GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: Ai Xin'an® (China) | SHR-1209 | SHR1209
recaticimab is an approved drug
Compound class:
Antibody
Comment: Recaticimab (SHR-1209) is an anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody.
|
| References |
|
1. Lamb YN. (2025)
Recaticimab: First Approval. Drugs, 85 (8): 1067-1072. [PMID:40545518] |
|
2. Sun Y, Lv Q, Guo Y, Wang Z, Huang R, Gao X, Han Y, Yao Z, Zheng M, Luo S et al.. (2024)
Recaticimab as Add-On Therapy to Statins for Nonfamilial Hypercholesterolemia: The Randomized, Phase 3 REMAIN-2 Trial. J Am Coll Cardiol, 84 (20): 2037-2047. [PMID:39505412] |
|
3. Xu M, Wang Z, Zhang Y, Liu Y, Huang R, Han X, Yao Z, Sun J, Tian F, Hu X et al.. (2024)
Recaticimab Monotherapy for Nonfamilial Hypercholesterolemia and Mixed Hyperlipemia: The Phase 3 REMAIN-1 Randomized Trial. J Am Coll Cardiol, 84 (20): 2026-2036. [PMID:39387764] |
